Kailos Genetics

KailosGenetics.com

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying genetic risks to common medications. The Kailos test is an easily accessible genetic test catered to your lifestyle.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

ILLUMINA LAUNCHES STRATEGIC RESEARCH COLLABORATION WITH ASTRAZENECA TO ACCELERATE DRUG TARGET DISCOVERY

Illumina, Inc. | October 12, 2022

news image

Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence o...

Read More

AZELASTINE, AN ANTIHISTAMINE NASAL SPRAY IDENTIFIED AS A PREVENTIVE OR POST-EXPOSURE ANTI-COVID-19 APPROACH

CEBINA | July 13, 2020

news image

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...

Read More

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

news image

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More

AI, Diagnostics

GENOMIC VISION ANNOUNCES LAUNCH OF FIBERSMART

Genomic Vision | March 08, 2023

news image

On March 7, 2023, Genomic Vision, a leading biotech company that develops products and services for the analysis and control of genome changes, launched FiberSmart®, an AI-based technology for automating the quantification and detection of fluorescent signals on combed DNA molecules. Initially available for the analysis of Replication Combing Assays (RCA), Genomic Vision's proprietary method for directly visualizing DNA replication kinetics at the single molecule level. ...

Read More
news image

Industrial Impact

ILLUMINA LAUNCHES STRATEGIC RESEARCH COLLABORATION WITH ASTRAZENECA TO ACCELERATE DRUG TARGET DISCOVERY

Illumina, Inc. | October 12, 2022

Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence o...

Read More
news image

AZELASTINE, AN ANTIHISTAMINE NASAL SPRAY IDENTIFIED AS A PREVENTIVE OR POST-EXPOSURE ANTI-COVID-19 APPROACH

CEBINA | July 13, 2020

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...

Read More
news image

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More
news image

AI, Diagnostics

GENOMIC VISION ANNOUNCES LAUNCH OF FIBERSMART

Genomic Vision | March 08, 2023

On March 7, 2023, Genomic Vision, a leading biotech company that develops products and services for the analysis and control of genome changes, launched FiberSmart®, an AI-based technology for automating the quantification and detection of fluorescent signals on combed DNA molecules. Initially available for the analysis of Replication Combing Assays (RCA), Genomic Vision's proprietary method for directly visualizing DNA replication kinetics at the single molecule level. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us